A Study of Ixazomib+Daratumumab+Dexamethasone (IDd) in Relapsed and/or Refractory Multiple Myeloma (RRMM)

PHASE2CompletedINTERVENTIONAL
Enrollment

61

Participants

Timeline

Start Date

March 13, 2018

Primary Completion Date

January 1, 2022

Study Completion Date

June 26, 2023

Conditions
Multiple Myeloma
Interventions
DRUG

Ixazomib

Ixazomib capsule.

DRUG

Daratumumab

Daratumumab IV infusion.

DRUG

Dexamethasone

Dexamethasone tablets.

Trial Locations (28)

10676

Evaggelismos General Hospital, Athens

11528

Alexandra General Hospital of Athens, Athens

26504

University General Hospital of Patras Panagia I Voithia, Patras

32308

SCRI - Florida Cancer Specialists - Panhandle, Tallahassee

44093

Hopital Hotel Dieu, Nantes

58014

SCRI - Tennessee Oncology - Nashville - Centennial, Nashville

59037

Hopital Claude Huriez, Lille

64132

Research Medical Center - Kansas City, Kansas City

69495

Centre Hospitalier Lyon Sud, Pierre-Bénite

75012

Hopital Saint-Antoine, Paris

77030

The University of Texas MD Anderson Cancer Center, Houston

77900

Fakultni Nemocnice Olomouc, Olomouc

80218

Colorado Blood Cancer Institute, Denver

92801

Pacific Cancer Medical Center, Anaheim

100 34

Fakultni Nemocnice Kralovske Vinohrady, Prague

708 52

Fakultni Nemocnice Ostrava, Ostrava - Poruba

625 00

Fakultni Nemocnice Brno, Brno

128 08

Onkologicka klinika Vseobecna fakultni nemocnice v Praze a 1, Prague

1081 HV

Vrije Universiteit Medisch Centrum, Amsterdam

8934 AD

Medisch Centrum Leeuwarden, Leeuwarden

3300 AK

Albert Schweitzer Ziekenhuis Dordwijk, Dordrecht

3015 CE

Erasmus Medisch Centrum, Rotterdam

3584 CX

Universitair Medisch Centrum Utrecht, Utrecht

31-501

Szpital Uniwersytecki w Krakowie, Krakow

36-200

Szpital Specjalistyczny w Brzozowie Podkarpacki Osrodek Onkologiczny im. Ks. B. Markiewicza, Brzozów

81-519

Szpitale Pomorskie Spolka z ograniczona odpowiedzialnoscia, Gdynia

41-500

Samodzielny Publiczny Zaklad Opieki Zdrowotnej Zespol Szpitali Miejskich, Chorzów

93-510

Wielospecjalistyczne Centrum Onkologii i Traumatologii im. M. Kopernika w Lodzi, Lodz

Sponsors

Lead Sponsor

All Listed Sponsors
lead

Takeda

INDUSTRY

NCT03439293 - A Study of Ixazomib+Daratumumab+Dexamethasone (IDd) in Relapsed and/or Refractory Multiple Myeloma (RRMM) | Biotech Hunter | Biotech Hunter